Advertisement
U.S. markets open in 2 hours 25 minutes
  • S&P Futures

    5,202.75
    -12.00 (-0.23%)
     
  • Dow Futures

    39,157.00
    -66.00 (-0.17%)
     
  • Nasdaq Futures

    18,179.75
    -51.75 (-0.28%)
     
  • Russell 2000 Futures

    2,043.90
    -5.90 (-0.29%)
     
  • Crude Oil

    82.55
    -0.17 (-0.21%)
     
  • Gold

    2,157.40
    -6.90 (-0.32%)
     
  • Silver

    25.12
    -0.14 (-0.55%)
     
  • EUR/USD

    1.0848
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.54
    +0.21 (+1.47%)
     
  • GBP/USD

    1.2683
    -0.0046 (-0.36%)
     
  • USD/JPY

    150.5580
    +1.4600 (+0.98%)
     
  • Bitcoin USD

    63,099.26
    -4,901.46 (-7.21%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,710.91
    -11.64 (-0.15%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

EMA panel recommends that use of Actelion's Uptravi may continue

ZURICH, Feb 10 (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe into five deaths in France among those using the pulmonary arterial hypertension medicine.

(Reporting by John Miller; Editing by Michael Shields)

Advertisement